Author

A. Skepner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Research Focus:protein folding & dynamics· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Ianari· 2 shared D. C. McKinney· 2 shared D. Porter· 2 shared K. M. Mulvaney· 2 shared M. Ranaghan· 2 shared W. R. Sellers· 2 shared A. E. Carpenter· 1 shared A. Hajjar· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Ianari

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

nELISA: A high-throughput, high-plex platform enables quantitative profiling of the inflammatory secretome

M. Dagher, G. Ongo, N. Robichaud, J. Kong, W. Rho, I. Teahulos, A. Tavakoli, S. Bovaird, S. Merjaneh, A. Tan, K. Edwardson, C. Scheepers, A. Ng, A. Hajjar, B. Sow, , D. Juncker

nELISA enables high-throughput, high-plex protein profiling of the inflammatory secretome, revealing 447 significant cytokine responses across multiple donors and conditions.

bioRxiv · Apr 17, 2023 · PreprintBioengineering

Discovery of a first-in-class inhibitor of the PRMT5-substrate adaptor interaction

D. C. McKinney, B. J. McMillan, M. Ranaghan, J. A. Moroco, M. Brousseau, Z. Mullin-Bernstein, M. O'Keefe, P. McCarren, M. F. Mesleh, K. M. Mulvaney, R. Singh, B. Bajrami, A. Skepner, D. E. Timm, D. Porter, , A. Ianari

The paper identifies a first-in-class inhibitor, BRD0639, that targets the PRMT5-PBM interaction, disrupting SAP binding and reducing substrate methylation in cancer cells.

bioRxiv · Feb 3, 2021 · PreprintCancer Biology

Molecular basis for substrate recruitment to the PRMT5 methylosome

K. M. Mulvaney, C. Blomquist, N. Acharya, R. Li, M. OKeefe, M. Ranaghan, M. Stokes, A. J. Nelson, S. S. Jain, J. Columbus, F. K. Bozal, A. Skepner, D. Raymond, D. C. McKinney, Y. Freyzon, , W. R. Sellers

The paper identifies a conserved peptide sequence in PRMT5 substrate adaptors that mediates their interaction with PRMT5 and shows its necessity for methylation of substrates like spliceosome, histones, and ribosome complexes.

bioRxiv · Aug 22, 2020Cancer Biology